Q2 EPS Estimate for CRISPR Therapeutics Boosted by Analyst

CRISPR Therapeutics AG (NASDAQ:CRSP) – Investment analysts at Brookline Capital Markets boosted their Q2 2026 earnings estimates for shares of CRISPR Therapeutics in a report issued on Tuesday, May 5th. Brookline Capital Markets analyst L. Cann now forecasts that the company will earn ($0.81) per share for the quarter, up from their prior estimate of ($1.16). The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($4.93) per share. Brookline Capital Markets also issued estimates for CRISPR Therapeutics’ Q3 2026 earnings at ($1.31) EPS, Q4 2026 earnings at ($1.69) EPS, FY2026 earnings at ($5.36) EPS, FY2027 earnings at ($5.05) EPS, FY2029 earnings at $35.57 EPS and FY2030 earnings at $128.35 EPS.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Tuesday, March 31st. The company reported ($1.28) earnings per share (EPS) for the quarter. CRISPR Therapeutics had a negative net margin of 13,856.54% and a negative return on equity of 25.66%. The business had revenue of $1.46 million for the quarter.

A number of other research firms also recently issued reports on CRSP. Citizens Jmp cut their target price on shares of CRISPR Therapeutics from $86.00 to $80.00 and set a “market outperform” rating on the stock in a research report on Friday, January 30th. Piper Sandler restated an “overweight” rating and set a $110.00 target price (up from $105.00) on shares of CRISPR Therapeutics in a research report on Tuesday, March 17th. Morgan Stanley restated an “underweight” rating and set a $33.00 target price on shares of CRISPR Therapeutics in a research report on Tuesday, February 17th. Citigroup upped their target price on shares of CRISPR Therapeutics from $80.00 to $82.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, Bank of America cut their target price on shares of CRISPR Therapeutics from $90.00 to $89.00 and set a “buy” rating on the stock in a research report on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $64.82.

CRISPR Therapeutics Stock Performance

CRISPR Therapeutics stock opened at $55.08 on Thursday. The company has a current ratio of 17.97, a quick ratio of 13.32 and a debt-to-equity ratio of 0.32. CRISPR Therapeutics has a 1 year low of $33.50 and a 1 year high of $78.48. The company has a market cap of $5.31 billion, a PE ratio of -8.86 and a beta of 1.74. The company’s 50-day moving average is $52.43 and its two-hundred day moving average is $54.51.

Institutional Trading of CRISPR Therapeutics

A number of large investors have recently bought and sold shares of CRSP. GSK plc bought a new stake in CRISPR Therapeutics during the 4th quarter worth approximately $168,890,000. Orbis Allan Gray Ltd increased its stake in CRISPR Therapeutics by 76.9% during the 2nd quarter. Orbis Allan Gray Ltd now owns 2,764,532 shares of the company’s stock worth $134,467,000 after purchasing an additional 1,201,600 shares in the last quarter. SR One Capital Management LP increased its stake in CRISPR Therapeutics by 94.4% during the 3rd quarter. SR One Capital Management LP now owns 2,038,763 shares of the company’s stock worth $132,132,000 after purchasing an additional 989,812 shares in the last quarter. State Street Corp grew its stake in shares of CRISPR Therapeutics by 35.6% during the 2nd quarter. State Street Corp now owns 3,270,596 shares of the company’s stock worth $159,082,000 after acquiring an additional 859,334 shares in the last quarter. Finally, ARK Investment Management LLC grew its stake in shares of CRISPR Therapeutics by 7.5% during the 4th quarter. ARK Investment Management LLC now owns 10,522,057 shares of the company’s stock worth $551,777,000 after acquiring an additional 735,084 shares in the last quarter. 69.20% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, CEO Samarth Kulkarni sold 10,020 shares of the stock in a transaction that occurred on Monday, March 23rd. The stock was sold at an average price of $46.78, for a total transaction of $468,735.60. Following the completion of the sale, the chief executive officer directly owned 255,501 shares of the company’s stock, valued at approximately $11,952,336.78. This represents a 3.77% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Naimish Patel sold 3,150 shares of the stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $48.26, for a total value of $152,019.00. Following the sale, the insider directly owned 13,143 shares of the company’s stock, valued at approximately $634,281.18. The trade was a 19.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 51,828 shares of company stock valued at $2,578,097. 4.30% of the stock is owned by corporate insiders.

CRISPR Therapeutics News Summary

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: Piper Sandler initiated/confirmed a Buy on CRISPR, giving investors a fresh constructive analyst view that can attract buyers. Crispr Therapeutics AG (CRSP) Gets a Buy from Piper Sandler
• Positive Sentiment: Chardan Capital reiterated a Buy on CRSP, reinforcing institutional support and signaling confidence in the company’s mid‑term value drivers. Chardan Capital Remains a Buy on Crispr Therapeutics AG (CRSP)
• Positive Sentiment: Analysts and commentators point to commercial momentum for Casgevy and upcoming H2 in‑vivo catalysts as a buy case—coverage highlighting revenue growth prospects supports upside expectations. Crispr Therapeutics Q1 Earnings: Casgevy Growth, H2 In-Vivo Catalysts Make Buy Case
• Positive Sentiment: Management will present at the Bank of America Global Healthcare Conference next week — a high‑visibility event that can drive renewed investor interest and provide updated commercial/programmatic color. CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference
• Neutral Sentiment: Coverage is mixed — a Globe & Mail roundup highlights conflicting analyst views across healthcare names (including CRSP), underscoring varied risk/reward perceptions among firms. Analysts Have Conflicting Sentiments on These Healthcare Companies
• Neutral Sentiment: HC Wainwright published FY2027 EPS estimates for CRSP (continuing negative EPS consensus), keeping longer‑term profitability expectations uncertain. HC Wainwright FY2027 Estimates
• Negative Sentiment: Q1 report showed a wider-than-expected loss and revenue miss, which pressured shares — although management highlighted Casgevy sales growth and strengthened cash after financing, the near‑term top‑line shortfall is a clear downside catalyst. CRISPR Therapeutics’ Q1 Loss Wider Than Expected, Sales Miss Estimates
• Negative Sentiment: Brookline Capital trimmed its FY2028 EPS forecast, signaling some analyst caution on longer-term profitability and valuation assumptions. Brookline Capital Lowers FY2028 EPS Estimate

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.